Unknown

Dataset Information

0

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.


ABSTRACT: Analysis of nucleotide variants is a cornerstone of cancer medicine. Although only 2% of the genomic sequence is protein coding, mutations occurring in these regions have the potential to influence protein structure or modification status and may have severe impact on disease aetiology. Proteogenomics enables the analysis of sample-specific nonsynonymous nucleotide variants with regard to their effect at the proteome and phosphoproteome levels. Here, we developed a proof-of-concept proteogenomics workflow and applied it to the malignant melanoma cell line A375. Initially, we studied the resistance to serine/threonine-protein kinase B-raf (BRAF) inhibitor (BRAFi) vemurafenib in A375 cells. This allowed identification of several oncogenic nonsynonymous nucleotide variants, including a gain-of-function variant on aurora kinase A (AURKA) at F31I. We also detected significant changes in abundance among (phospho)proteins, which led to reactivation of the MAPK signaling pathway in BRAFi-resistant A375 cells. Upon reconstruction of the multiomic integrated signaling networks, we predicted drug therapies with the potential to disrupt BRAFi resistance mechanism in A375 cells. Notably, we showed that AURKA inhibition is effective and specific against BRAFi-resistant A375 cells. Subsequently, we investigated amino acid variants that interfere with protein posttranslational modification (PTM) status and potentially influence A375 cell signaling irrespective of BRAFi resistance. Mass spectrometry (MS) measurements confirmed variant-driven PTM changes in 12 proteins. Among them was the runt-related transcription factor 1 (RUNX1) displaying a variant on a known phosphorylation site S(Ph)276L. We confirmed the loss of phosphorylation site by MS and demonstrated the impact of this variant on RUNX1 interactome.

SUBMITTER: Schmitt M 

PROVIDER: S-EPMC8603206 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.

Schmitt Marisa M   Sinnberg Tobias T   Bratl Katrin K   Zittlau Katharina K   Garbe Claus C   Macek Boris B   Nalpas Nicolas C NC  

Molecular & cellular proteomics : MCP 20211019


Analysis of nucleotide variants is a cornerstone of cancer medicine. Although only 2% of the genomic sequence is protein coding, mutations occurring in these regions have the potential to influence protein structure or modification status and may have severe impact on disease aetiology. Proteogenomics enables the analysis of sample-specific nonsynonymous nucleotide variants with regard to their effect at the proteome and phosphoproteome levels. Here, we developed a proof-of-concept proteogenomic  ...[more]

Similar Datasets

2021-11-04 | PXD018305 | Pride
| S-EPMC3246694 | biostudies-other
| S-EPMC8445818 | biostudies-literature
| S-EPMC3758344 | biostudies-literature
| S-EPMC6684922 | biostudies-literature
| S-EPMC2915408 | biostudies-literature
| S-EPMC4279367 | biostudies-literature
| S-EPMC4930524 | biostudies-literature
| S-EPMC3549295 | biostudies-literature
| S-EPMC7191094 | biostudies-literature